NSA-789

DRUG4 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer

Conditions

Alzheimer DiseaseHealthyHealthy SubjectsSchizophrenia

Phase 1

Study Evaluating the Safety, Tolerability and Pharmacokinetics of NSA-789 in Healthy Japanese Male Subjects

CompletedNCT00619736

Wyeth is now a wholly owned subsidiary of PfizerHealthy

Start: 2008-03-31End: 2008-09-30Updated: 2009-01-30

Study Evaluating the Safety and Tolerability of NSA-789

CompletedNCT00633048

Wyeth is now a wholly owned subsidiary of PfizerHealthy

Start: 2008-03-31End: 2008-05-31Target: 64Updated: 2009-02-17

Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

CompletedNCT00795730

Wyeth is now a wholly owned subsidiary of PfizerAlzheimer Disease, Healthy Subjects

Start: 2009-01-31End: 2009-05-31Updated: 2021-08-20

Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder

WithdrawnNCT00892021

Wyeth is now a wholly owned subsidiary of PfizerSchizophrenia

Start: 2009-05-31End: 2009-10-31Updated: 2021-08-20